1. Home
  2. ESPR vs CCD Comparison

ESPR vs CCD Comparison

Compare ESPR & CCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Logo Calamos Dynamic Convertible & Income Fund

CCD

Calamos Dynamic Convertible & Income Fund

HOLD

Current Price

$25.00

Market Cap

662.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
CCD
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
731.9M
662.0M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESPR
CCD
Price
$3.13
$25.00
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.75
N/A
AVG Volume (30 Days)
9.9M
90.7K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
10.61%
EPS Growth
60.71
N/A
EPS
N/A
N/A
Revenue
$403,135,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.31
N/A
52 Week Low
$0.95
$19.17
52 Week High
$4.18
$26.10

Technical Indicators

Market Signals
Indicator
ESPR
CCD
Relative Strength Index (RSI) 69.52 47.98
Support Level $3.11 $23.81
Resistance Level $3.18 $24.64
Average True Range (ATR) 0.01 0.58
MACD -0.03 -0.00
Stochastic Oscillator 75.00 49.84

Price Performance

Historical Comparison
ESPR
CCD

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

About CCD Calamos Dynamic Convertible & Income Fund

Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.

Share on Social Networks: